BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) saw its stock soar 7.83% in the after-hours trading session on Wednesday, following the company's impressive fourth-quarter results and an optimistic outlook for the full year 2025.
In the fourth quarter, BioMarin reported adjusted earnings of $0.92 per diluted share, significantly outperforming analysts' expectations of $0.53 per share. The company's revenue for the quarter stood at $747.3 million, surpassing the consensus estimate of $713.4 million.
The strong performance was driven by robust sales of BioMarin's key products, including VOXZOGO for achondroplasia, which saw a 42% year-over-year increase in revenue to $208 million during the quarter. The company's Enzyme Therapies portfolio also contributed significantly, with sales rising 9% year-over-year.
Looking ahead to 2025, BioMarin provided an optimistic outlook, projecting non-GAAP earnings per share in the range of $4.20 to $4.40 on revenue between $3.1 billion and $3.2 billion. This guidance surpassed analysts' expectations of $4.15 in earnings per share and $3.10 billion in revenue.
The company's solid performance and upbeat guidance reflect its strategic focus on expanding the global reach of its innovative therapies and advancing its robust pipeline of potential treatments for rare genetic disorders.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.